From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD20
Clinical data
Trade names Bexxar
AHFS/ monograph
MedlinePlus a609013
CAS Registry Number 192391-48-3 YesY
ATC code V10XA53 (sequential regimen with 131I form)
DrugBank DB00081 YesY
UNII 0343IGH41U YesY
KEGG D08622 YesY
Chemical data
Formula C6416H9874N1688O1987S44
Molecular mass 143859.7 g/mol
 N (what is this?)  (verify)

Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[1] It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][3]

This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[4]